

67. (Amended) The composition of matter of Claim 66 comprising a PRO1122 polypeptide comprising amino acid residues 1 to 197 of SEQ ID NO:3 in combination with a pharmaceutically acceptable carrier.

68. (Amended) The composition of matter of Claim 66 which comprises a PRO1122 polypeptide comprising amino acid residues 19 to 197 of SEQ ID NO:3 in combination with a pharmaceutically acceptable carrier.

C1  
But D1

69. (Amended) An article of manufacturing comprising:  
a container; and  
a composition of matter comprising an isolated polypeptide having at least 80% amino acid sequence identity to:  
(a) amino acid residues 1 to 197 of SEQ ID NO:3,  
(b) amino acid residues 19 to 197 of SEQ ID NO:3,  
(c) the amino acids encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203654, or  
(d) the amino acids encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203654 lacking its associated signal peptide encoding region; wherein said isolated polypeptide is capable of inducing the production of TNF- $\alpha$  in human leukemia monocytic THP-1 cells.

Please add new Claims 71-81 as follows:

But D2  
C2

--71. (New) An isolated polypeptide comprising at least 80% amino acid sequence identity to:  
(a) the amino acid residues 1 to 197 of SEQ ID NO:3,  
(b) the amino acid residues 19 to 197 of SEQ ID NO:3,  
(c) the amino acids encoded by the full-length coding sequence of the cDNA deposited